# EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

> **NCT07163325** · PHASE1 · RECRUITING · sponsor: **Epics Therapeutics** · enrollment: 48 (estimated)

## Conditions studied

- Advanced Solid Tumor (Phase 1)

## Interventions

- **DRUG:** EP102

## Key facts

- **NCT ID:** NCT07163325
- **Lead sponsor:** Epics Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2027-11
- **Final completion:** 2028-11
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07163325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07163325, "EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07163325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*